Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

NCT07792538

ClinicalTrials.gov

Trial ID
T-ctgov-NCT07792538
Registry
ClinicalTrials.gov
NCT number
NCT07792538
Asset
psilocybin (investigator-led; PEX010 capsules, 25 mg and 5 mg)
Sponsor, as registered
ARQ National Psychotrauma Centre
Phase
PHASE2
Indication
Posttraumatic Stress Disorder (PTSD)
Status
NOT_YET_RECRUITING
Start date
2026-12
Primary completion
2028-12
Registered countries
Netherlands
Sites
1

The sponsor's registered location list, which states intent rather than approval.

clinicaltrials.govctgov registryverified 2026-09-08

Notes on the record

First posted 2026-08-28, last update posted 2026-08-28. Enrollment 12 ESTIMATED; single group, no masking (open-label); start 2026-12 ESTIMATED. secondaryIdInfos carries no CTIS identifier, so the registry cross-reference points the wrong way again, as with NCT05870540. Cited in Issue 12 as the Data Point. Fields read from the ClinicalTrials.gov v2 API record. countries is the distinct country list across all registered locations; site_count is the number of location entries, which counts a country once per site, not once per country.

Company

Through psilocybin (investigator-led; PEX010 capsules, 25 mg and 5 mg): ARQ Centrum'45

Cited in

Issues quoting NCT07792538 in their own text.